Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Barcelona, Spain, 1 September: Primary angioplasty (with stent implantation) is the most effective therapy for acute myocardial infarction (AMI), but it is not available to many patients, even though most European countries have sufficient resources (ie, catheterisation laboratories) for its wider use. The Stents 4 Life initiative was a study aiming to analyze the use of primary angioplasty in the treatment of AMI in 27 European countries.
Data were collected from national infarction or angioplasty registries, on AMI epidemiology and treatment and on angioplasty centres and procedures in each country.Findings showed that the frequency (annual incidence) of hospital admission for any AMI varied between 90 and 312 events per 100,000 population per year; the incidence of serious AMIs (with ST-elevations on ECG - STEMI) ranging from 44-142 per thousand.Primary angioplasty (primary PCI) was the dominant reperfusion strategy in 17 countries and thrombolysis in nine countries. The application of a PCI strategy varied between 5 and 92% (in all STEMI patients), and use of thrombolysis (an older, less effective form of therapy) between 0 and 55%. Curent guidelines recopmmend that any reperfusion treatment (angioplasty or thrombolysis) should be used ideally in 100% of these patients; however, we found it used only in 37–93% of STEMI patients.The number of primary angioplasty procedures per million population per year varied among countries between 20 and 970. The mean population served by a single primary angioplasty centre varied between 0.3 and 7.4 million inhabitants. In those coutries offering primary angioplasty services to most of their STEMI patients, population varied between 0.3 and 1.1 million per centre.In-hospital mortality of all consecutive STEMI patients varied between 4.2 and 13.5%, of patients treated by thrombolysis between 3.5 and 14%, and of patients treated by primary PCI between 2.7 and 8%.The time reported from symptom onset to the first medical contact (FMC) varied between 60 and 210 minutes, FMC to needle time for thrombolysis between 30 and 110 minutes, and FMC to balloon time for primary angioplasty between 60 and 177 minutes.Most north, west and central European countries used primary angioplasty for the majority of their STEMI patients. The lack of organised primary angioplasty networks in some countries was associated with fewer patients overall receiving some form of reperfusion therapy. Primary angioplasty rates above 600 per million population are needed to provide this treatment for most STEMI patients in Europe.
This press release accompanies both a presentation and an ESC press conference given at the ESC Congress 2009 in Barcelona. Written by the investigator himself/herself, this press release does not necessarily reflect the opinion of the European Society of Cardiology.
© 2017 European Society of Cardiology. All rights reserved